It is not realistic to expect increased investment in medicines research in the EU or quicker access to new treatments for its citizens if member states insist on the lowest possible prices and highest government rebates, according to Nathalie Moll, Director General of Efpia, the European Federation of Pharmaceutical Industries and Associations. Ms Moll’s comments follow the publication of Efpia’s annual WAIT (Waiting to Access Innovative Therapies) report, which showed a picture of widening inequality among member states.
